Company intelligence / Profile preview

DiagnoCure

Quebec City, Quebec, Canadaprnewswire.com ↗

Ownership: Private
Development stage: Other

Overview

DiagnoCure developed molecular diagnostic tests for prostate and colorectal cancers. Its main products included the Previstage GCC test for colorectal cancer staging using the guanylyl cyclase C marker, and the PROGENSA PCA3 urine assay for prostate cancer risk assessment. The company focused on outlicensing its technologies in later years before ceasing operations.

Therapeutic areas: Oncology
Modalities: Molecular diagnostic testGene expression analysisSNP genotyping
Industry: Molecular Diagnostics

Partnerships

Licensed PROGENSA PCA3 technology to Hologic; other partnerships not specified but focused on outlicensing in later years.

Beyond the preview

Go deeper on DiagnoCure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DiagnoCure.

Explore the full profile